Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GeneDx Holdings (WGS) Free Cash Flow (2020 - 2025)

GeneDx Holdings (WGS) has disclosed Free Cash Flow for 6 consecutive years, with -$17.6 million as the latest value for Q4 2025.

  • On a quarterly basis, Free Cash Flow fell 2276.68% to -$17.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $14.3 million, a 150.05% increase, with the full-year FY2025 number at $14.3 million, up 150.05% from a year prior.
  • Free Cash Flow was -$17.6 million for Q4 2025 at GeneDx Holdings, down from $19.8 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of $19.8 million in Q3 2025 to a low of -$92.1 million in Q3 2022.
  • A 5-year average of -$35.6 million and a median of -$35.5 million in 2023 define the central range for Free Cash Flow.
  • Peak YoY movement for Free Cash Flow: tumbled 20456.41% in 2021, then soared 412.44% in 2025.
  • GeneDx Holdings' Free Cash Flow stood at -$48.4 million in 2021, then crashed by 34.97% to -$65.3 million in 2022, then skyrocketed by 54.29% to -$29.9 million in 2023, then soared by 97.51% to -$742000.0 in 2024, then plummeted by 2276.68% to -$17.6 million in 2025.
  • Per Business Quant, the three most recent readings for WGS's Free Cash Flow are -$17.6 million (Q4 2025), $19.8 million (Q3 2025), and $4.1 million (Q2 2025).